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Results: Thirty-four patients were enrolled and treated. Patient 
characteristics were: ECOG performance status 0 in 24 patients, 1 in 
10 patients, median age 63 years (range 39-78), and gender male 20, 
female 14. Dose-escalation was possible to erlotinib 150mg/day for 
both regimens during chemoradiotherapy. Grade 3/4 leukopenia and 
neutropenia were noted in both arms. No Grade 4 therapy-related non-
hematologic toxicities were noted. For arm A, grade 3 toxicities during 
chemoradiotherapy were: esophagitis (3), vomiting (1), ototoxicity (1), 
diarrhea (2), dehydration (3), pneumonitis (1). For arm B, esophagitis 
(6) was the dominant grade 3 toxicity. Rash developed in 7 patients 
(21%). Twenty-seven patients (79%) completed their assigned regimen 
and were evaluable for response (Arm A - 12, Arm B - 15). Reasons 
for discontinuation were: adverse event (3), withdrawal of consent (2), 
non-compliance (1) and non-cancer related early death (1). Overall 
radiologic responses were (Arm A/B): Complete Response (0/1), 
Partial Response (8/9), Stable Disease (1/2) and Progressive Disease 
(3/3). Intention-to-treat 1- and 2- overall survivals were 47% and 21%, 
respectively. Overall and median survivals between the two arms were 
not signiﬁcantly different. In the patients who developed a rash (7), 1 
complete and 4 partial responses were observed. This group of patients 
had a trend towards improved overall survival (log-rank 0.07).
Conclusion: The addition of erlotinib to two standard chemoradio-
therapy regimens is feasible and does not increase toxicities associated 
with chemoradiotherapy.
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Randomized phase II trial using concomitant chemoradiation 
plus induction (I) or consolidation (C) chemotherapy (CT) for 
unresectable stage III non-small cell lung cancer (NSCLC) patients 
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Background: Neither the optimal sequence of treatment nor the best 
combination CT is yet well-deﬁned in p receiving concomitant therapy. 
Methods: P with unresectable stage III NSCLC with IK > 70 and 
weight loss < 5% were initially randomized to sequential treatment 
(arm A), concurrent CT/TRT followed by consolidation (C) CT (arm 
B) or induction (I) CT followed by CT/TRT (arm C). Based on RTOG 
9410 results, arm A was closed and the study continues with two 
concomitant arms (B, C). All p receive 2 cycles of Docetaxel (D) 40 
mg/m2 d1, 8 plus Gemcitabine (G) 1200 mg/m2 d1, 8 as I or C therapy. 
Concomitant treatment includes D 20 mg/m2 and carboplatin (Cb) AUC 
2 weekly plus 60 Gy TRT. 
Results: From May 01 to Jun 06, 151 p were included (A: 19, B: 66, C: 
66). Due to the early closing of arm A, only data of evaluable arms B 
and C p are shown: toxicity 127 p (B: 63, C: 64) and response 110 p (B: 
53, C: 57). All groups are well-matched for baseline disease character-
istics. Toxicity grade 3-4 by CTC and RTOG criteria was: esophagitis 
19.5% (arm B) and 14.2% (arm C); pneumonitis 8.8 % (arm B) and 
10% (arm C). Neutropenia during I or C therapy: 22 % (B) and 6.2 
% (C). Thrombocytopenia 8% (B) and 3% (C). Neutropenia during 
concomitant therapy: 6.3% (B) and 6% (C). No thrombocytopenia or 
severe anemia was found during CT/TRT. The reduction CT rate was 
superior in consolidation (35%) than in induction (15%) and in arm C 
during concomitant therapy (22.4% C, 6.5% B). Delay of CT dose was 
similar in B and C arms during I or C (22% B, 20% C) but superior 
in arm C during concurrent treatment (19.6% B, 30.6% C). The ﬁnal 
response rates were 57% (B) and 56.9% (C). A trend for longer time to 
progression (TTP) was found (B: 7.6 months (m) and C: 9.2 m; p= 0.12) 
but with similar overall survival (B: 14.3 m and C: 14.7 m; p= 0.38). 
Conclusions: Non-platinum CT plus concomitant chemoradiation offer 
similar response rate and a favorable hematological toxicity proﬁle in 
unresectable stage III NSCLC p. No differences in OS but a trend for 
longer TTP in the arm C (I followed by concurrent approach) has been 
found. Final data are pending in order to select the best sequence for 
further studies.
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Background: Combined modality therapy using both chemotherapy 
and TRT is the standard treatment option in unrectable stage III 
NSCLC. Our group demonstrated a superiority of MVP with concur-
rent TRT over that with sequential TRT (Furuse et al. JCO 17, 1999). 
Currently, concurrent chemoradiotherapy plays a pivotal role in this pa-
tient population. However, the optimal chemotherapy regimen remains 
unclear. Weekly chemotherapy with concurrent TRT has acceptable 
toxicities and expected efﬁcacy. We conducted a randomized phase III 
trial to compare the efﬁcacy and toxicity of weekly chemotherapy with 
concurrent TRT against MVP by a non-inferiority design. 
Methods: Patients (pts) were randomly assigned to 3 regimens; MVP: 
cisplatin (80 mg/m2 on days 1, 29), vindesine (3 mg/m2 on days 1, 8, 
29, 36) and mitomycin (8 mg/m2 on days 1, 29) with concurrent TRT 
(60 Gy). After then, pts received 2 courses of consolidation chemo-
therapy with MVP; IC: weekly irinotecan (20 mg/m2)/carboplatin(AUC 
2) for 6 weeks and TRT (60 Gy) followed by 2 courses of irinotecan(50 
mg/m2)/carboplatin(AUC 5); PC: weekly paclitaxel (40 mg/m2)/carbo-
platin (AUC 2) and TRT (60 Gy) followed by 2 courses of paclitaxel 
(200 mg/m2)/carboplatin (AUC 5). The primary endpoint was overall 
survival; secondary endpoints were time to progression, response, and 
toxicity. 
Results: From Sep 2001 to Sep 2005, 456 pts were randomized; 429 
pts had evaluated responses. Pretreatment characteristics were well-bal-
anced between 3 arms (median age 63 years (30-74), PS0/1 41/55 %, 
Ad/Sq /others 43/ 45/12 %). The achievement rates of full treatment in 
MVP, IC and PC were 39.9, 29.7, and 49.3 %; those of full-dose TRT / 
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2 courses of consolidation chemotherapy were 81.1/41.3 %, 41.4/29.7 
% and 59.7/50.0 %, respectively. Major toxicities were as follows; G4 
neutropenia in MVP, IC, PC were 76.9, 13.1, 4.2 % (p<.001), and G3-4 
non-hematological toxicities (decrease in PS, and febrile neutropenia) 
were 13.3, 6.2, 4.2 % (p=.01), and 29.4, 6.9, 4.9 % (p<.001), respec-
tively. The overall response rates were 65.7 % (95%CI 57.9-73.5), 58.6 
% (95%CI 50.5-66.1) and 62.9 % (95%CI 55.0-70.8), in MVP, IC and 
PC, respectively. Complete analysis will be ﬁxed in Oct 2008. 
Conclusions: Weekly PC with TRT appears good compliance with 
high achievement rate and MVP appears poor compliance with severe 
hematological and non-hematological toxicities.
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Phase III study comparing a preoperative (PRE) and a 
perioperative (PERI) chemotherapy (CT) with two different 
CT regimens in resectable stage I-II non-small cell lung cancer 
(NSCLC): the IFCT 0002 protocol
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Background: The association of surgery and chemotherapy is now 
a standard in stages IA-III. The primary objective of this trial was to 
deﬁne the best timing of CT (all before surgery versus perioperative). 
Another objective was to compare two regimens, gemcitabine-cisplatin 
(GP) and paclitaxel-carboplatin (TC) (GP: Gemcitabine 1250 mg/m2/
d1, 8 and cisplatin 75 mg/m2/d1 q3 wk; TC: Paclitaxel 200 mg/m2/d1 
and carboplatin AUC 6, q3 wk).
Methods: 528 stage I-II resectable NSCLC were randomized to 4 
parallel arms: A: 2 GP + in responders, 2 GP, then surgery, B: 2 GP + 
surgery + in responders, 2 GP, C: 2 TC cycles + in responders, 2 TC 
then surgery, D: 2 TC + surgery + in responders, 2 TC. Quality of life 
was evaluated with the EORTC QLQ C30 - LC13 questionnaire at days 
1, 42 and 147. Results were analyzed two by two: PRE (A+C) versus 
PERI (B+D) and GP (A+B) versus TC (C+D).
Results: 1) The addition of 2 additionnal preoperative CT cycles in 
responders did not inﬂuence tumor volume, intratumoral necrosis, 
pleural, venous or intrapulmonary lymphatic invasions. Pathological 
complete response rates were not statistically different (PRE: 6.3%, 
PERI: 7.6%, GP: 8.2%, TC: 5.6%). Objective responses were simi-
lar (PRE: 50.6%, PERI: 50.9%, GP: 52.2%, TC: 49.2%) 2) 30-day 
postoperative mortality were identical whether the patient received 2 
or 4 cycles before surgery. Similarly, iatrogenic mortality at 6 months 
did not differ with the number of preoperative CT cycles (PRE:3%, 
PERI:3.21%). The main toxicities differs betweeen GP and TC only for 
G ≥2 neuropathy at 6 months (GP: 6.5%, TC: 24.4%, p<10-3) and G ≥2 
nausea (GP: 22.17%, TC: 4.22%, p<10-3) .3) Proportions of pts receiv-
ing cycles 3 and 4 were higher when they were given before surgery 
than after surgery (PRE: 90.4%, PERI:75.2 %, p=.0011). Percentages 
of non operated pts after CT were identical in both groups (PRE: 4.5%, 
PERI: 4.3%). 4) There was no difference in Quality of Life between 
the 4 groups. At 6 months, decrease of health status, different function-
ning and symptoms did not differ between the 4 arms in responding pts 
(except for alopecia).
Conclusions: 1- GP and TC were both effective and safe, although 
with different toxicity proﬁles. 2- Results of pathological response 
suggested that 2 preoperative cycles might be as effective as 4 cycles. 
3- Dose intensity was higher when all chemotherapy was given before 
surgery compared to both before and after surgery. 4- Quality of life 
decrease in the same proportions in each group within the 6 months 
after randomization.
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Background: A previous IPD meta-analysis (BMJ 1995;311:899) 
that suggested cisplatin-based CT may have a role in the treatment of 
NSCLC has been updated. This includes RCTs, regimens and outcomes 
that were not available in 1995. The meta-analysis examines the role 
of CT in 7 treatment comparisons. Here we report on Comparison 1: 
surgery + CT versus surgery alone and Comparison 3: surgery + RT + 
CT versus surgery + RT.
Methods: RCTs were identiﬁed by comprehensive search strategies. 
Updated IPD were collected, checked and re-analysed. Results from 
RCTs were combined using the stratiﬁed (by trial) logrank test to calcu-
late individual and pooled hazard ratios (HRs).
Results: Comparison 1
IPD were obtained from 30 RCTs and 8147 patients, representing 
95% of all known randomised patients, adding 18 RCTs and 5835 
patients to the 1995 analyses. Median follow-up is 5.3 years. 15 RCTs 
used a cisplatin combination without Tegafur/Tegafur+Uracil (UFT), 
8 RCTs used Tegafur/UFT without cisplatin and 7 RCTs used Tega-
fur/UFT and cisplatin. There is a signiﬁcant beneﬁt of CT on survival 
(HR=0.86, 95% CI 0.81-0.93, p<0.0001), with an absolute beneﬁt of 
4% (from 60% to 64%) at 5 years. Results were similar for recurrence-
free survival (HR=0.83, 95%CI 0.77-0.91, p<0.0001, 14 RCTs) local 
(HR=0.76, 95% CI 0.66-0.87, p<0.0001, 12 RCTs) and distant recur-
rence-free interval (HR=0.83, 95% CI 0.74-0.93, p=0.001, 12 RCTs).
Comparison 3
IPD were obtained from 11 RCTs and 2,626 patients (12% with incom-
plete resection), representing 86% of all known randomised patients, 
adding 5 RCTs and 1956 patients to the 1995 analysis. Median follow-
up is 6.3 years. 10 RCTs used sequential radio-chemotherapy, 8 RCTs 
used cisplatin + vinca alkaloid/etoposide, 1 used cisplatin + Tegafur 
and 2 used other cisplatin regimens. There is a signiﬁcant beneﬁt of 
CT on overall survival (HR=0.88, 95% CI 0.80-0.96, p=0.0062), with 
an absolute beneﬁt of 5% (from 29% to 34%) at 5 years. Results were 
similar for recurrence-free survival (HR=0.84, 0.77-0.93, p=0.0006, 
